# Quanta Therapeutics

> Privately held, clinical-stage biopharmaceutical company in South San Francisco, California
> (founded 2018, second site in Radnor, Pennsylvania) developing oral allosteric small-molecule
> medicines for RAS-driven cancers. Its proprietary high-throughput Second Harmonic Generation (SHG)
> optical platform detects protein conformational change to find allosteric modulators of signaling
> complexes, an approach the company calls conformational blockade of RAS. Clinical programs are
> direct multi-KRAS inhibitors: QTX3034 (G12D-preferring, Phase 1 monotherapy and with cetuximab),
> QTX3544 (G12V-preferring, IND cleared January 2025) and QTX3046 (first patient dosed June 2024),
> across pancreatic, colorectal, lung and endometrial cancers.

This file is generated by API Evangelist from the public profile at
https://github.com/api-evangelist/quanta-therapeutics — Quanta Therapeutics does not publish an
llms.txt of its own.

## APIs

Quanta Therapeutics publishes no public API, developer portal, API documentation, SDK, or
machine-readable API contract (OpenAPI, AsyncAPI, GraphQL, MCP, A2A) as of 2026-08-05. Probes of the
corporate host for /openapi.json, /swagger.json, /api-docs, /docs, /graphql, /llms.txt and every
/.well-known/ discovery path returned HTTP 404, and api.quantatx.com, developer.quantatx.com and
docs.quantatx.com do not resolve in DNS. The company's "platform" is laboratory instrumentation —
an SHG optical assay used internally for drug discovery — not a software product with an interface
third parties can call.

## Company

- [Website](https://www.quantatx.com/): Corporate site (a single static page with anchor sections)
- [About](https://www.quantatx.com/#about): Company overview
- [Platform](https://www.quantatx.com/#platform): Second Harmonic Generation (SHG) discovery platform
- [Pipeline](https://www.quantatx.com/#pipeline): Development programs
- [Investigational Agents](https://www.quantatx.com/pipeline/investigational-agents/): QTX3034, QTX3544, QTX3046
- [Leadership](https://www.quantatx.com/#leadership): Team
- [News](https://www.quantatx.com/#news): Press releases
- [Careers](https://www.quantatx.com/#careers): Open roles
- [Contact](https://www.quantatx.com/#contact): info@quantatx.com — 2 Tower Place, 17th Floor, South San Francisco, CA 94080
- [LinkedIn](https://www.linkedin.com/company/quanta-therapeutics)

## Recent announcements

- [2026-03-05](https://www.quantatx.com/news/030526/): Direct multi-KRAS inhibitors retain activity against resistance mechanisms
- [2025-10-24](https://www.quantatx.com/news/102425/): Positive Phase 1 data for QTX3034
- [2025-10-13](https://www.quantatx.com/news/101325/): First clinical data for QTX3034 at AACR-NCI-EORTC
- [2025-04-28](https://www.quantatx.com/news/042825/): Late-breaking QTX3544 data at AACR Annual Meeting
- [2025-01-08](https://www.quantatx.com/news/010825/): IND clearance for QTX3544
- [2024-06-27](https://www.quantatx.com/news/06-27-24/): First patient dosed in the QTX3046 Phase 1/1b trial
- [2023-05-22](https://www.quantatx.com/news/05-22-23/): Series D financing of over $50 million
- [2021-10-26](https://www.quantatx.com/news/10-26-21/): $60 million Series C financing

## Artifacts

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/quanta-therapeutics/refs/heads/main/apis.yml): APIs.json 0.20 profile
- [Domain security](https://raw.githubusercontent.com/api-evangelist/quanta-therapeutics/refs/heads/main/security/quanta-therapeutics-domain-security.yml): TLS/DNS/email-auth probe
- [Well-known probe](https://raw.githubusercontent.com/api-evangelist/quanta-therapeutics/refs/heads/main/well-known/quanta-therapeutics-well-known.yml): /.well-known/ and contract-discovery probe results